2020
DOI: 10.3389/fmed.2020.00281
|View full text |Cite
|
Sign up to set email alerts
|

Utility of [18F] Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography for Staging and Therapy Response Evaluation in Pediatric Rhabdomyosarcoma: A Case Series and Literature Review

Abstract: Background: The role of [ 18 F] fluoro-deoxyglucose [[ 18 F] FDG] positron emission tomography (PET)/computed tomography (CT) in pediatric rhabdomyosarcoma (RMS) is not well-established. This manuscript explores the role of staging and therapy response evaluation of PET/CT in a series of patients with RMS. Methods: Thirteen consecutive patients with pathologically proven RMS underwent baseline PET/CT scan and a second PET/CT for evaluation of therapy response. Maximum standardized uptake value (SUV max), mean … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…The value of PET/MR in clinical applications remains to be established, and we hope this innovative technology will provide more accurate diagnosis and ultimately improve patient prognosis. In addition, a study illustrated that metabolic parameters obtained from baseline PET/CT were potential to select patients sensitive to treatment ( 31 ). Features of patients including unfavorable sites of the primary tumor, older patient age at initial presentation, the alveolar subtype, and regional lymph node involvement are considered to be poor prognostic factors for RMS ( 5 , 32 ).…”
Section: Discussionmentioning
confidence: 99%
“…The value of PET/MR in clinical applications remains to be established, and we hope this innovative technology will provide more accurate diagnosis and ultimately improve patient prognosis. In addition, a study illustrated that metabolic parameters obtained from baseline PET/CT were potential to select patients sensitive to treatment ( 31 ). Features of patients including unfavorable sites of the primary tumor, older patient age at initial presentation, the alveolar subtype, and regional lymph node involvement are considered to be poor prognostic factors for RMS ( 5 , 32 ).…”
Section: Discussionmentioning
confidence: 99%